Skip to main content
Fig. 2 | BMC Ophthalmology

Fig. 2

From: Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years

Fig. 2

SD-OCT images pre- and post-FAc implant in patients with chronic DMO. a. Right eye of 42 year old male with type 1 diabetes and a 4 year history of DMO treated with previous anti-VEGF, triamcinolone and grid laser. DMO (a1) resolved by 8 months (a2) b. Left vitrectomised eye of a patient with 5 year history of DMO. Treated with anti-VEGF, triamcinolone and grid laser. DMO (b1) resolved by 5 months (b2). c. Right eye of 45 year old male chronic non attender with type 1 diabetes and a 1.2 year history of DMO treated with anti-VEGF. DMO (c1) resolved by 3 months (c2). d. Left vitrectomised eye of 53 year old female with type 1 diabetes and 1 year history of DMO treated with anti-VEGF. DMO (d1) resolved by 5 months (d2)

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us